PER-010-10未知未知
AN OPEN-LABEL RANDOMIZED, PARALLEL, TWO-ARM PHASE II STUDY COMPARING BMS-690514 + LETROZOLE WITH LAPATINIB + LETROZOLE IN RECURRENT AND METASTATIC BREAST CANCER PATIENTS WHO ARE HORMONE RECEPTOR POSITIVE DESPITE HER2 STATUS AND WHO RELAPSED WHILE RECEIVING OR AFTER COMPLETING ADJUVANT ANTIENDOCRINE THERAPY
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 100（—）
- 性别
- Female
入选标准
- •1) Informed written consent approved by the IRB / IEC voluntarily signed and dated form in accordance with the guidelines.
- •2) Invasive breast cancer documented histologically positive for ER + and / or PgR + in 10% of tumor cells or more, with tumor tissue from previous surgery available for analysis of ER / PR, EGFR, PTEN and PIK3CA.
- •3) Patients must have previously received adjuvant therapy for breast cancer with tamoxifen or exemestane anastraozol. the sequential use of antihormonal agents are allowed.
- •4) Patients receiving cytotoxic chemotherapy (adjuvant setting in metastatic, or neoadjuvant) therapy must have completed at least 4 weeks before the first dose of randomized study medication.
排除标准
- •1) Patients who have received prior hormonal therapy for metastatic disease.
- •2) Patients who have received prior hormonal therapy for metastatic disease.
- •3) Symptomatic patients with brain metastases.
- •4) Patients with signs or symptoms suggestive of understanding
研究者
相似试验
招募中
不适用
PHASE 2 STUDY OF AGEN2034 AS MONOTHERAPY OR IN COMBINATION THERAPY WITH AGEN1884 IN SECOND-LINE CERVICAL CANCER-C53 Malignant neoplasm of cervix uteriMalignant neoplasm of cervix uteriC53PER-047-19Agenus Inc.,
进行中（未招募）
不适用
A Phase 2 trial for patients with prostate cancer to receive study drugsof CP-751,871 in combination with Docetaxel/Prednisone orDocetaxel/Prednisone alone.Metastatic hormone refractory (androgen indepedent) progressive prostate cancer (HRPC)MedDRA version: 14.0Level: LLTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-002717-21-DEPfizer Inc. 235 East 42nd Street, New York, NY 10017, USA200
进行中（未招募）
1 期
A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRACTORY (ARM B) PATIENTS WITH HORMONE INSENSITIVE PROSTATE CANCER - n/aMetastatic hormone refractory (androgen indepedent) progressive prostate cancer (HRPC)MedDRA version: 13.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-002717-21-GBPfizer Inc,235 East 42nd Street, New York,NY 10017200
进行中（未招募）
1 期
A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRACTORY (ARM B) PATIENTS WITH HORMONE INSENSITIVE PROSTATE CANCEREstudio en fase 2, aleatorizado, no comparativo, abierto, multicéntrico, con dos grupos, de CP-751,871 en combinación con docetaxel/prednisona en pacientes con cáncer de próstata resistente a hormonas sin quimioterapia previa (Grupo A) o refractarios a docetaxel /prednisona (Grupo B)Metastatic hormone refractory(androgen independent) progressive prostate cancer (HRPC)Cáncer de próstata progresivo metastásico resistente a hormonas (CPRH) (independiente de andrógenos)EUCTR2005-002717-21-ESPfizer, S.A.120
进行中（未招募）
不适用
A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRACTORY (ARM B) PATIENTS WITH HORMONE INSENSITIVE PROSTATE CANCEREUCTR2005-002717-21-NLPfizer Inc. 235 East 42nd Street, New York, NY 10017